Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features-Reference-Cited by-同舟云学术

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features

Published:2018-06-06 Issue:8 Volume:103 Page:3010-3018
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Pariani Nadia¹,Willis Mark²,Muller Ilaria³,Healy Sarah²,Nasser Taha²,McGowan Anne¹,Lyons Greta¹,Jones Joanne⁴,Chatterjee Krishna¹,Dayan Colin³,Robertson Neil²,Coles Alasdair⁴,Moran Carla¹

Affiliation:

1. University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom

2. Division of Psychological Medicine and Clinical Neuroscience, Department of Neurology, Cardiff University, University Hospital of Wales, Cardiff, United Kingdom

3. Thyroid Research Group, Cardiff University, University Hospital of Wales, Cardiff, United Kingdom

4. Department of Clinical Neurosciences, Addenbrooke’s Hospital, Cambridge, United Kingdom

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/103/8/3010/25506574/jc.2018-00359.pdf

Reference25 articles.

1. Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis;Greenwood;Ther Immunol,1994

2. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis;Hill-Cawthorne;J Neurol Neurosurg Psychiatry,2012

3. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy;Havrdova;Neurology,2017

4. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings;Coles;Neurology,2017

5. Alemtuzumab treatment of multiple sclerosis: long term safety and efficacy;Tuohy;J Neurol Neurosurg Psychiatry,2015

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thyroid and Adrenal Dysfunction in Hemoglobinopathies Before and After Allogeneic Hematopoietic Cell Transplant;Journal of the Endocrine Society;2023-10-31

2. Pharmacological treatment of Graves’ disease: present and future;L'Endocrinologo;2023-10-31

3. Hyperthyroidism following transplantation and SARS‐CoV‐2 exposure;Pediatric Blood & Cancer;2023-10-04

4. Alemtuzumab induces severe orbitopathy in relapsing–remitting multiple sclerosis;Journal of Neurology;2023-09-29

5. Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease;The Journal of Clinical Endocrinology & Metabolism;2023-09-14